$HCSG

3 stories mentioning HCSGUpdated 8d ago

Every FINWIRES story that references HCSG, newest first.

Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) marginally advancing.Repligen (RGEN) has agreed to acquire BioLife Solutions (BLFS) in a deal valued at $1.5 billion, the companies said. Shares of Repligen were down more than 4% and BioLife Solutions stock was up more than 2% pre-bell.Royalty Pharma (RPRX) said it will pay up to $425 million, including a $125 million upfront payment, to Neurimmune for a 3% to 4% royalty on worldwide net sales of its interest in AstraZeneca's (AZN) cliramitug. Royalty Pharma stock was down more than 1% pre-bell.Healthcare Services Group (HCSG) shares were 0.8% higher after the company reported that it swung to a Q2 net income as revenue increased during the period.

$AZN$BLFS$HCSG$IBB$RGEN$RPRX$XLV

Wire98d ago

UBS Adjusts Price Target on Healthcare Services to $27 From $25, Maintains Buy Rating

Healthcare Services (HCSG) has an average rating of overweight and mean price target of $26.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $22.35, Change: $-0.54, Percent Change: -2.36%

$HCSG

Sectors99d ago

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

Health care stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) 0.3% higher.Boston Scientific (BSX) shares were up more than 5% after the company reported higher Q1 adjusted earnings and net sales.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at more than $8 billion, Reuters reported, citing people familiar with the matter. Inhibrx Biosciences stock was up more than 48% pre-bell.Healthcare Services Group (HCSG) shares were up more than 22% after the company reported higher Q1 earnings and revenue.

$BSX$HCSG$IBB$INBX$MRK$XLV

Track with the FINWIRES app suite

FolioX

Track HCSG in your portfolio

WheelAI

Analyze HCSG options with the wheel strategy

StockInsider

See market sentiment on HCSG